Brief: Helix Biopharma Corp. Initiates Enrollment for Study Of Lung Cancer Drug
13/09/2018 13:18
Sept 13 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. INITIATES ENROLLMENT OF THE SECOND
LAST
COHORT IN U.S. COMBINATION TREATMENT STUDY OF ITS LUNG CANCER
DRUG CANDIDATE L-DOS47
Source text for Eikon: ID:nGNX9Gtfc
Further company coverage: HBP.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020